Gradual High Dosing of Glofitamab Results in high Response Rates in Patients with relapsed/refractory (R/R) Mantle Cell Lymphoma (MCL), most of whom had failed prior Bruton's Tyrosine Kinase Inhibitor (BTKi) Therapy

ONCOLOGY RESEARCH AND TREATMENT(2022)

引用 0|浏览8
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要